

**RPG LIFE SCIENCES LIMITED**

Regd. Off.: RPG House  
463, Dr. Annie Besant Road  
Worli, Mumbai 400030, India  
Tel: +91-22-24981650 / 66606375  
Fax: +91-22-24970127  
Email: info@rpglifesciences.com  
www.rpglifesciences.com  
CIN : L24232MH2007PLC169354

July 19, 2024

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department  
Floor  
25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

**Symbol: RPGLIFE**

**Scrip code: 532983**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting of the Company held on July 19, 2024**

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Friday, July 19, 2024, *inter-alia*, considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2024.

The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 03:00 p.m. and concluded at 5.45 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

**RAJESH RAMESH SHIRAMBEKAR**  
Digitally signed by RAJESH RAMESH SHIRAMBEKAR  
Date: 2024.07.19 17:49:08 +05'30'

Rajesh Shirambekar  
Head – Legal & Company Secretary



**Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S R B C & CO LLP**

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

**per Aruna Kumaraswamy**

Partner

Membership No.: 219350

UDIN: 24219350BKCSYT3085



Place: Mumbai


Date: July 19, 2024

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024**


Particulars	(Rs. in Lakhs)			
	Quarter ended			Year ended
	30-Jun-24	31-Mar-24	30-Jun-23	31-Mar-24
	Unaudited	Audited (Refer Note 3)	Unaudited	Audited
1 Revenue from Operations	16,542	12,699	14,778	58,205
2 Other Income	237	165	181	721
<b>3 Total Income (1+2)</b>	<b>16,779</b>	<b>12,864</b>	<b>14,959</b>	<b>58,926</b>
<b>4 Expenses</b>				
(a) Cost of Materials Consumed	3,237	2,803	3,047	12,065
(b) Purchases of Stock-in-Trade	2,489	1,492	1,666	6,118
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(225)	(151)	305	270
(d) Employee Benefits Expense	3,274	3,208	3,279	13,215
(e) Finance Costs	15	14	7	45
(f) Depreciation and Amortisation Expense	529	449	421	1,707
(g) Other Expenses	3,860	3,275	3,257	13,722
<b>Total Expenses</b>	<b>13,179</b>	<b>11,090</b>	<b>11,982</b>	<b>47,142</b>
<b>5 Profit before tax (3-4)</b>	<b>3,600</b>	<b>1,774</b>	<b>2,977</b>	<b>11,784</b>
<b>6 Income tax expenses</b>				
a. Current Tax	951	545	792	3,254
b. Deferred Tax	(27)	(95)	(25)	(236)
<b>Total tax expenses</b>	<b>924</b>	<b>450</b>	<b>767</b>	<b>3,018</b>
<b>7 Profit for the period (5-6)</b>	<b>2,676</b>	<b>1,324</b>	<b>2,210</b>	<b>8,766</b>
<b>8 Other Comprehensive Income</b>				
(i) Items that will not be reclassified to Profit or Loss	2	(82)	2	(75)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(1)	22	(1)	19
<b>Other Comprehensive Income Net of Tax</b>	<b>1</b>	<b>(60)</b>	<b>1</b>	<b>(56)</b>
<b>9 Total Comprehensive Income for the period (7+8)</b>	<b>2,677</b>	<b>1,264</b>	<b>2,211</b>	<b>8,710</b>
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323
11 Other Equity				36,162
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic (in Rs.)	16.18	8.01	13.36	53.01
(b) Diluted (in Rs.)	16.18	8.01	13.36	53.01

**Notes:**

- The above unaudited financial results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on July 19, 2024.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Figures of the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and unaudited published year to date figure up to 31 December, 2023, which were subject to limited review.

**SIGNED FOR IDENTIFICATION**  
BY  
  
**S R B C & CO LLP**  
**MUMBAI**

For RPG Life Sciences Limited

  
Yugal Sikri  
DIN: 07576560  
Managing Director  
Mumbai, July 19 2024